Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Pharmadrug Inc
C.PHRX
Alternate Symbol(s):
LMLLF
Medical Care
Cannabis
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural...
medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:PHRX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(1)
•••
Cann2019
X
View Profile
View Bullboard History
Comment by
Cann2019
on Jun 28, 2024 1:17pm
RE:RE:RE:RE:RE:HALT!!
Dang dang dang when zero? or another reverse split then back to zero lol
(1)
•••
Cann2019
X
View Profile
View Bullboard History
Comment by
Cann2019
on Jun 13, 2024 2:43pm
RE:RE:RE:RE:HALT!!
Dang just about there lol
(1)
•••
Cann2019
X
View Profile
View Bullboard History
Comment by
Cann2019
on Oct 24, 2023 11:19am
RE:RE:RE:HALT!!
Dang 7 to 1 and then back to zero and delist lol
(1)
•••
Cann2019
X
View Profile
View Bullboard History
Comment by
Cann2019
on Aug 22, 2023 4:06pm
RE:RE:HALT!!
Almost there and then whats next... delist
(1014)
•••
Patrick2Linton
X
View Profile
View Bullboard History
Post by
Patrick2Linton
on Jul 15, 2023 2:29pm
Much anticipated deep drill program to start
One of Goldy/fishercats pumps is about to kick off the much anticipated deep drill program. This is the game changing drill program that everyone in the know has been waiting for . This deep drill
...more
(1)
•••
Cann2019
X
View Profile
View Bullboard History
Comment by
Cann2019
on May 10, 2023 4:06pm
RE:HALT!!
Done done and done
(2247)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on May 08, 2023 3:21pm
PharmaDrug Announces Cease Trade Order
Toronto, Ontario--(Newsfile Corp. - May 8, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is announcing that the Ontario Securities Commission
...more
(823)
•••
Bentley2000
X
View Profile
View Bullboard History
Post by
Bentley2000
on May 08, 2023 12:37pm
HALT!!
What's going on???
(1)
•••
Cann2019
X
View Profile
View Bullboard History
Post by
Cann2019
on Apr 19, 2023 4:08pm
Done and done
When zero? Next week or so?
(1)
•••
kingtroller
X
View Profile
View Bullboard History
Post by
kingtroller
on Oct 05, 2022 10:05am
Cancer fighting drug
https://themarketherald.ca/pharmadrug-advances-programs-in-oncology-and-infectious-disease-through-completion-of-cgmp-drug-substance-manufacturing-2022-10-04/?utm_source=stockhouse.com&utm_medium
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 25, 2022 8:02am
New Press Release - PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues
PharmaDrug completes all necessary research on lead DMT-analogue to support filing of provisional patent describing novel therapeutic and delivery device for treatment of glaucoma in Q4, 2022PharmaDrug extends contract with investigators at Johns Hopkins University in support of forthcoming (Q4...
read article.
(68)
•••
Toppick9
X
View Profile
View Bullboard History
Post by
Toppick9
on Aug 22, 2022 10:21am
To many share outstanding
After great news last week we couldn't keep the gains because of the large amount outstanding. Buy Silo instead. 10 million out and will ha big news soon!
(3076)
•••
Goldy63
X
View Profile
View Bullboard History
Comment by
Goldy63
on Aug 19, 2022 2:39pm
RE:PharmaDrug Successfully Completes Key Milestone to Support .
Amazing News , Great Vol small pop. Another huge step IMO. Keep up the good work Dan . Cheers.
(11)
•••
swim
X
View Profile
View Bullboard History
Post by
swim
on Aug 19, 2022 8:29am
PharmaDrug Successfully Completes Key Milestone to Support .
PharmaDrug Successfully Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001, Its Patented, Orally Available Version of Cepharanthine for Oncology and
...more
(2247)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Aug 10, 2022 5:23pm
Microdose Announces The 2nd Annual Microdose Awards
Miami, Florida--(Newsfile Corp. - August 9, 2022) - Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is excited to announce the lineup of categories for the 2nd
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >